Dermatology

Galderma said the FDA has accepted the company’s Biologics License Application for the therapy based on data from the trials.

The most common adverse events in patients using oral corticosteroids for more than 90 days included fracture, hyperlipidemia, myocardial infarction, and avascular necrosis.

Delgocitinib cream from LEO Pharmaceuticals showed superior efficacy compared to cream vehicle and was well tolerated over 16 weeks.

Patients with acne who adhered to a mediterranean diet and supplemented with omega-3s saw improvements in inflammatory and non-inflammatory lesions.

Researchers aimed to address the extent of stigmatization’s effect on the mental health of adolescents with chronic skin disorders.

Calcitonin gene-related peptides are known to trigger vasodilation and inflammation.

Ustekinumab-ttwe, a biosimilar to ustekinumab (Stelara) is expected launch in the US in February 2025.

The commercial product is expected to be available by the end of July.

Test your pharmacy news knowledge with our weekly quiz.

A study found that having a high level of melanoma knowledge was significantly correlated with having risk factors for the disease, such as skin ultraviolet radiation vulnerability and lighter hair color.

The strongest independent predictors of becoming adherent to dermatology follow-up included younger age and prior outpatient visits.

Skin complications are common in patients with diabetes, but pharmacists can recommend several easy measures to help.

Patients with advanced cancer can experience malignant wounds, which can have a negative impact on quality of life.

Check out these can’t-miss dermatology stories published this month.

Check out these top featured stories from Drug Topics in May 2024.

Research exploring the growing role of artificial intelligence (AI) in health care sheds a light on the potential of the technology to improve skin cancer detection and awareness among patients and health care professionals.

Berdazimer topical gel is the first in its class and is the only topical prescription medication to treat molluscum contagiosium that can be applied by patients or caregivers outside of a medical setting.

Cutting through the noise of social media is key when educating patients on how to make better choices for their skin.

Warm weather means one thing: People are eager to be outdoors. Although sun protection is paramount, sunscreen options can be daunting. How can pharmacists help?

For Melanoma and Skin Cancer Awareness Month, Drug Topics sat down with Colleen McCabe, PharmD, BCOP, to glean clinical insights into promoting skin cancer awareness in the community pharmacy.

Test your pharmacy news knowledge with our weekly quiz.

Spring and summer not only bring sunshine, but also stronger UV rays. Whether you are barbecuing, swimming, or taking a hike, skin protection is paramount while soaking up the sunshine.

Recent research exploring the gut-skin connection shows that dietary modifications and probiotic supplements may help skin conditions like acne, atopic dermatitis, and rosacea.

The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.

Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.

Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.

The average US household spent $645 on OTC products in 2022.

A lack of diversity in clinical trials has hampered health care providers from understanding the nuances of diseases across specific patient populations.

Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.

In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.